GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                               
                                     
                             Compound class: 
                                                            Antibody
                                 
                                
                                    
                                        Comment: LY2928057 is an investigational anti-ferroportin monoclonal being developed as a treatment for anemia. A search of patents reveals WO2010065496 A1 as Eli Lilly's application covering the development and use of anti-ferroportin 1 monoclonal antibodies [1]. The HGNC approved gene symbol for ferroportin 1 is SLC40A1.
                                    
                                 
                            
                            
                          
                                
                                    
                                
                          
                                   
                                   
                                  
                                    
                                    
                                     | 
                                    
| Bioactivity Comments | 
| In WO2010065496 the only humanised clone accompanied with a Kd for ferropotin binding is human 3D8. The Kd value is 3.37nM [1]. This clone also inhibits ferrorortin internalisation and degradation with an IC50 value of 13.7nM. We have tagged SLC40A1 as the primary target of this antibody based on the patent contents. | 
| Selectivity at transporters | ||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | |||||||||||||||||||||||||||||||||
                                                                        
                                                                         
  | 
                                                                ||||||||||||||||||||||||||||||||||